Buscar resultados de ensayos clínicos
Gout - 58 Studies Found
| Estado | Estudiar |
| Completed |
Nombre del estudio: Novel Methods for Ascertainment of Gout Flares -A Pilot Study Condición: Gout Fecha: 2016-07-28 Intervenciones:
|
| Completed |
Nombre del estudio: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. Condición: Acute Gout Fecha: 2010-03-02 Intervenciones:
|
| Completed |
Nombre del estudio: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study Condición: Acute Gout Fecha: 2009-12-09 Intervenciones:
|
| Completed |
Nombre del estudio: Long-Term Safety of Febuxostat in Subjects With Gout. Condición: Gout Fecha: 2005-09-12 Intervenciones:
|
| COMPLETED |
Nombre del estudio: Effect of Tigulixostat on the Pharmacokinetics of Theophylline Condición: Gout Fecha: 2026-01-10 Intervenciones: 300 mg oral dose |
| NOT_YET_RECRUITING |
Nombre del estudio: Reverse Transcriptase Inhibitors in Aicardi Gouti�res Syndrome Condición: Aicardi Gouti�res Syndrome Fecha: 2026-01-10 Intervenciones: Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate.This is |
| Completed |
Nombre del estudio: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Condición: Gout Fecha: 2026-01-10 Intervenciones: Xanthine Oxidase Inhibitor |
| Completed |
Nombre del estudio: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Condición: Acute Gout Flare Fecha: 2026-01-10 Intervenciones: An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later |
| Completed |
Nombre del estudio: Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout Condición: Gout Fecha: 2026-01-10 Intervenciones: Low, medium or high dose (Part 1); Selected dose(s) (Part 2) |
| Completed |
Nombre del estudio: Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout Condición: Gout Fecha: 2026-01-10 Intervenciones: increasing dose of D-0120 |